Dynamics of Helicobacter pylori infection as a determinant of progression of gastric precancerous lesions: 16-year follow-up of an eradication trial
- PMID: 28647684
- PMCID: PMC5742304
- DOI: 10.1136/gutjnl-2016-311685
Dynamics of Helicobacter pylori infection as a determinant of progression of gastric precancerous lesions: 16-year follow-up of an eradication trial
Abstract
Objective: To evaluate the long-term effect of cumulative time exposed to Helicobacter pylori infection on the progression of gastric lesions.
Design: 795 adults with precancerous gastric lesions were randomised to receive anti-H. pylori treatment at baseline. Gastric biopsies were obtained at baseline and at 3, 6, 12 and 16 years. A total of 456 individuals attended the 16-year visit. Cumulative time of H. pylori exposure was calculated as the number of years infected during follow-up. Multivariable logistic regression models were used to estimate the risk of progression to a more advanced diagnosis (versus no change/regression) as well as gastric cancer risk by intestinal metaplasia (IM) subtype. For a more detailed analysis of progression, we also used a histopathology score assessing both severity and extension of the gastric lesions (range 1-6). The score difference between baseline and 16 years was modelled by generalised linear models.
Results: Individuals who were continuously infected with H. pylori for 16 years had a higher probability of progression to a more advanced diagnosis than those who cleared the infection and remained negative after baseline (p=0.001). Incomplete-type IM was associated with higher risk of progression to cancer than complete-type (OR, 11.3; 95% CI 1.4 to 91.4). The average histopathology score increased by 0.20 units/year (95% CI 0.12 to 0.28) among individuals continuously infected with H. pylori. The effect of cumulative time of infection on progression in the histopathology score was significantly higher for individuals with atrophy (without IM) than for individuals with IM (p<0.001).
Conclusions: Long-term exposure to H. pylori infection was associated with progression of precancerous lesions. Individuals infected with H. pylori with these lesions may benefit from eradication, particularly those with atrophic gastritis without IM. Incomplete-type IM may be a useful marker for the identification of individuals at higher risk for cancer.
Keywords: H. pylori; Latin America; OLGA; OLGIM; atrophy; dysplasia; eradication; gastric cancer; intestinal metaplasia.
© Article author(s) (or their employer(s) unless otherwise stated in the text of the article) 2018. All rights reserved. No commercial use is permitted unless otherwise expressly granted.
Conflict of interest statement
Competing interests: None declared.
Figures
Comment in
-
Effect of cumulative time of Helicobacter pylori infection on gastric precancerous lesions?Turk J Gastroenterol. 2018 Jul;29(4):524-525. doi: 10.5152/tjg.2018.270618. Turk J Gastroenterol. 2018. PMID: 30249574 Free PMC article. No abstract available.
References
-
- Correa P. Human gastric carcinogenesis: a multistep and multifactorial process—first American Cancer Society award lecture on cancer epidemiology and prevention. Cancer Res. 1992;52:6735–40. - PubMed
-
- Correa P, Haenszel W, Cuello C, et al. A model for gastric cancer epidemiology. Lancet. 1975;2:58–60. - PubMed
-
- Correa P, Haenszel W, Cuello C, et al. Gastric precancerous process in a high risk population: cohort follow-up. Cancer Res. 1990;50:4737–40. - PubMed
-
- de Vries AC, van Grieken NC, Looman CW, et al. Gastric cancer risk in patients with premalignant gastric lesions: a nationwide cohort study in the Netherlands. Gastroenterology. 2008;134:945–52. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
- T32 DK007673/DK/NIDDK NIH HHS/United States
- R29 CA077955/CA/NCI NIH HHS/United States
- P30 DK058404/DK/NIDDK NIH HHS/United States
- R01 AT004821/AT/NCCIH NIH HHS/United States
- I01 BX001453/BX/BLRD VA/United States
- UL1 RR024975/RR/NCRR NIH HHS/United States
- R01 DK058587/DK/NIDDK NIH HHS/United States
- R01 DK053620/DK/NIDDK NIH HHS/United States
- P01 CA028842/CA/NCI NIH HHS/United States
- R01 CA077955/CA/NCI NIH HHS/United States
- R01 CA190612/CA/NCI NIH HHS/United States
- P01 CA116087/CA/NCI NIH HHS/United States
- R01 DK073902/DK/NIDDK NIH HHS/United States
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical